The Basic Principles Of PARP-1-IN-3
MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre examine To guage various intravenous doses of sifalimumab, in Grownup people with dermatomyositis or polymyositis (NCT00533091). Primary trial targets were to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis peopl